BeyondSpring Inc.

BeyondSpring Inc. is a clinical stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs. The company's lead asset, Plinabulin, is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanisms. Plinabulin has been administered to over 700 cancer patients and is being developed for various cancer indications as a direct anti-cancer agent with the safety benefit of reducing chemotherapy-induced neutropenia (CIN). Following a successful phase 3 study (DUBLIN-3) in NSCLC, Plinabulin is in a confirmatory global phase 3 study for second- and third-line NSCLC with epidermal growth factor receptor (EGFR) wild type after progression on prior immune checkpoint inhibitors. BeyondSpring is also developing three small molecule immune agents, which are currently in pre-clinical stages. The company founded and owns an equity stake in SEED Therapeutics Inc. (SEED). SEED utilizes a proprietary Targeted Protein Degradation (TPD) drug discovery platform, or "molecular glue" technology, to develop therapeutic agents. SEED advanced its wholly owned lead oncology asset, a novel RBM39 degrader, into phase 1 clinical studies in January 2026. SEED partners with Eli Lilly and Co. and Eisai Co., Ltd. to discover and develop new chemical entities through its TPD platform for oncology and central nervous system (CNS) diseases, among others. Plinabulin is a differentiated microtubule modulator with different binding and kinetics from other microtubule stabilizing or depolymerizing agents.